News
![Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?: https://g.foolcdn.com/editorial/images/769056/big-fish-eating-little-fish.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBODFWYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--70745744f13d62845890feab24d83363c8059be5/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/big-fish-eating-little-fish.jpg?locale=us)
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?
Two companies stand at the center of the obesity drug market right now. Novo Nordisk continues to rake in money from its weight-loss drug Wegovy (and from off-label usage of its type 2 diabetes drug
![Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?: https://g.foolcdn.com/editorial/images/768645/investor-ponders-phone-and-laptop-stock-charts.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNTlUYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--846dfa9c69ac803b8d89d98de10b662af4ae091c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-ponders-phone-and-laptop-stock-charts.jpg?locale=us)
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
Sarepta Therapeutics (NASDAQ: SRPT) could have a serious new competitor on the horizon. According to some fresh clinical data from Regenxbio (NASDAQ: RGNX), another biotech, the company is making
![2 Dirt Cheap Dividend Stocks to Buy and Hold: https://g.foolcdn.com/editorial/images/768347/patient-taking-medicine.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK3RRYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ca0ddca7223881199e46793161e996413ba07d82/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/patient-taking-medicine.jpg?locale=us)
2 Dirt Cheap Dividend Stocks to Buy and Hold
Dividend stocks are great for several reasons. Some use the regular payouts they offer to complement their income, whether in retirement or otherwise, while others reinvest the money to boost
![3 Pharmaceutical Stocks to Buy Hand Over Fist in March: https://g.foolcdn.com/editorial/images/767295/drug-development-pharmaceutical-pharma-research-researchers-doctors-1.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBKzFRYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--260887e99f4960ab33daf01c40ceff1d4e7b148f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/drug-development-pharmaceutical-pharma-research-researchers-doctors-1.jpg?locale=us)
3 Pharmaceutical Stocks to Buy Hand Over Fist in March
Pharmaceutical companies play a tremendous role in modern healthcare. While sometimes controversial, drugmakers design medicine to treat some of the worst ailments plaguing society and constantly
![Have $2,000? 2 Magnificent Stocks Ready for a Bull Run: https://g.foolcdn.com/editorial/images/768356/young-businesswoman-with-laptop-in-meeting-smiling.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd2RRYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f69588defc451ade44700df138c4c95146690d97/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/young-businesswoman-with-laptop-in-meeting-smiling.jpg?locale=us)
Have $2,000? 2 Magnificent Stocks Ready for a Bull Run
Stocks across a range of industries and sectors have dealt with unique challenges over the last few years. While some companies are still dealing with the effects of a slowdown in growth following
![Have $2,500? 2 Superior Growth Stocks to Buy in 2024: https://g.foolcdn.com/editorial/images/768357/cant-believe-it-shocked-looking-at-phone.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMHhQYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f0cc766e8b65d6ec4341506b7c72e3f2abd9a233/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/cant-believe-it-shocked-looking-at-phone.jpg?locale=us)
Have $2,500? 2 Superior Growth Stocks to Buy in 2024
Stocks have been off to a very bullish start in 2024, and investors seem increasingly optimistic about the overall state of the market and the global economy. Now, that's not to say there aren't
![2 Medical Device Stocks to Buy Hand Over Fist in March: https://g.foolcdn.com/editorial/images/768037/medical-professional-smiling.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOWhPYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dc69de3bb659f245cf17e5331ed0814a40e77e5a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/medical-professional-smiling.jpg?locale=us)
2 Medical Device Stocks to Buy Hand Over Fist in March
A good way to invest in the healthcare industry's continued growth is by targeting businesses that make medical devices. Such equipment aids physicians in surgery, helps patients recover, and can
![2 Biotech Stocks to Buy Hand Over Fist in March: https://g.foolcdn.com/editorial/images/767744/doctor-and-patient-in-a-hospital-room.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFpPYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6f3f52fd9bc3971965a377dd4a5f7dc1797b25f8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctor-and-patient-in-a-hospital-room.jpg?locale=us)
2 Biotech Stocks to Buy Hand Over Fist in March
Could this be the year biotech stocks bounce back? The industry has been in a slump over the past couple of years, but it started 2024 with a bang. The SPDR S&P Biotech ETF, which tracks an industry
![Why Victoria's Secret Stock Plummeted Today: https://g.foolcdn.com/editorial/images/768494/clothing-rack-store-sale-shopping.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMXhPYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b7f08d3ce52c0145954fc8f3a0ec7bac29f6ebe7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/clothing-rack-store-sale-shopping.jpg?locale=us)
Why Victoria's Secret Stock Plummeted Today
Shares of Victoria's Secret (NYSE: VSCO) plummeted 29.7% on Thursday after the lingerie, clothing, and beauty-products retailer announced reasonably solid quarterly results but followed with
![Recursion Pharmaceuticals Stock Has 33% Upside, According to 1 Wall Street Analyst: https://g.foolcdn.com/editorial/images/768100/two-scientists-work-at-lab-bench-with-scope.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOEZOYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--945d5743ac1b53ffd9731b74deef3260452380f9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/two-scientists-work-at-lab-bench-with-scope.jpg?locale=us)
Recursion Pharmaceuticals Stock Has 33% Upside, According to 1 Wall Street Analyst
On Monday, Keybanc analyst Scott Schoenhaus revised his price target on Recursion Pharmaceuticals (NASDAQ: RXRX) upward, opining the stock would climb by 33% and hit $16. The call came days after
![1 Wall Street Analyst Thinks Pfizer Stock Is Going to $45. Is It a Buy Around $26?: https://g.foolcdn.com/editorial/images/768104/investors-holding-printouts-talk-to-each-other-at-computer.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN1JOYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e9908c19e9320a5b5e78080ab6bad21a51fd851e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investors-holding-printouts-talk-to-each-other-at-computer.jpg?locale=us)
1 Wall Street Analyst Thinks Pfizer Stock Is Going to $45. Is It a Buy Around $26?
Per Cantor Fitzgerald analyst Louise Chen's calculations published March 4, Pfizer's (NYSE: PFE) stock is going to climb by around 75% to reach or surpass $45 over the coming quarters. Chen's
![Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter: https://mms.businesswire.com/media/20240305044213/en/2055849/5/Stelo_Pickleball.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeTlMYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--77bf14bc754e4704fd5a8e353c3a39dfc6d396c2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Stelo_Pickleball.jpg?locale=us)
Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom – the first glucose
![3 Biopharma Stocks You Don't Want to Miss in the New Bull Market: https://g.foolcdn.com/editorial/images/767685/investor-inspects-papers-on-a-couch.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNzFLYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3eb7fa7ddb044deb31f0298bde0e277c5cb0e23f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investor-inspects-papers-on-a-couch.jpg?locale=us)
3 Biopharma Stocks You Don't Want to Miss in the New Bull Market
It's not always a good idea to chase trends in a bull market, but sometimes the new wave of promising companies is more than a fad. In the biotech and pharma industries, right now is an exciting
![3 High-Yield S&P 500 Dividend Stocks Down More Than 28% to Buy Now and Hold at Least a Decade: https://g.foolcdn.com/editorial/images/767798/investment-presentation-getty.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd2xLYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c12d4e9b199b2eaa3a3d806de00c6b6ec618b369/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/investment-presentation-getty.jpg?locale=us)
3 High-Yield S&P 500 Dividend Stocks Down More Than 28% to Buy Now and Hold at Least a Decade
Rising tides don't always lift all boats. The S&P 500 index reached new all-time highs several times since 2024 began, but many of its components have not participated in the rally.
With most
![Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced compelling new clinical evidence supporting the use of Dexcom
![Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst: https://g.foolcdn.com/editorial/images/767473/researchers-pipette-samples-at-lab-bench.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd1JKYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f6e8f936063cdb6c4249fda051214056abb12400/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/researchers-pipette-samples-at-lab-bench.jpg?locale=us)
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
On Feb. 20, Wedbush financial analyst Andreas Argyrides restated his price target for Sarepta Therapeutics (NASDAQ: SRPT) stock, claiming that its shares would reach $224, rising 73% in the process
![1 S&P 500 Dividend Stock Down 56% to Buy and Hold Forever: https://g.foolcdn.com/editorial/images/767641/scientist-looking-through-microscope.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMVpJYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dce8f62ddde9646a42b491b8a8a68e9a388bf618/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientist-looking-through-microscope.jpg?locale=us)
1 S&P 500 Dividend Stock Down 56% to Buy and Hold Forever
Keep winners, ditch losers. That's usually not bad advice for investors. There's one big problem, though: Sometimes long-term winners temporarily look like losers.
Even the biggest and the best
![Ozempic Won't Sink This Medical Device Stock's Prospects -- Quite the Opposite: https://g.foolcdn.com/editorial/images/767012/diabetes-patient-adjusting-device.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOGhIYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8d1b92e714a667c09d6bf3464858a22a997f16b8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/diabetes-patient-adjusting-device.jpg?locale=us)
Ozempic Won't Sink This Medical Device Stock's Prospects -- Quite the Opposite
Anti-obesity drugs rose in popularity last year, helping the leaders in this market -- notably Eli Lilly and Novo Nordisk -- crush the market. However, some medical device specialists got the wrong
![1 Magnificent S&P 500 Dividend Stock Down 56% to Buy and Hold Forever: https://g.foolcdn.com/editorial/images/767211/tracking-investments-wealth-family-planning.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNkpIYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--de9cfd1b1c8077a0d19b83524a73dd264959b440/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/tracking-investments-wealth-family-planning.jpg?locale=us)
1 Magnificent S&P 500 Dividend Stock Down 56% to Buy and Hold Forever
Given its key role in the fight against COVID-19, the fact that Pfizer (NYSE: PFE) shares are down 56% from their 2021 peak isn't entirely surprising. Demand for its COVID-19 vaccine (Comirnaty) and
![1 Wall Street Analyst Thinks Biogen Stock Is Going to $311. Is It a Buy Around $223?: https://g.foolcdn.com/editorial/images/767026/scientist-works-at-lab-bench.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK2RHYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--888b935d2e86af0f5dd121832d2c103f976ba11d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/scientist-works-at-lab-bench.jpg?locale=us)
1 Wall Street Analyst Thinks Biogen Stock Is Going to $311. Is It a Buy Around $223?
On Feb. 20, Cantor Fitzgerald analyst Eric Schmidt restated his aggressive price target for Biogen, (NASDAQ: BIIB) estimating that the biopharmaceutical stock will rise by 39% to reach roughly $311
![Is AbbVie Stock a Buy Now?: https://g.foolcdn.com/editorial/images/766565/pharmacist-talking-to-patient.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNU5FYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--8fdec8eca42b75f2236f1927f67d049c6b8eb0db/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/pharmacist-talking-to-patient.jpg?locale=us)
Is AbbVie Stock a Buy Now?
Pharmaceutical giant AbbVie (NYSE: ABBV) is undergoing significant changes. Last year, the company lost U.S. patent exclusivity for its biggest cash cow, immunosuppressant Humira, and is now seeing
![CRISPR Therapeutics Stock Has 32% Upside, According to 1 Wall Street Analyst: https://g.foolcdn.com/editorial/images/766837/lab-research-scientists-women-in-stem.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMlpFYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--28fc368b7fccb30cf2cc098661d39c9239c1a8c7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/lab-research-scientists-women-in-stem.jpg?locale=us)
CRISPR Therapeutics Stock Has 32% Upside, According to 1 Wall Street Analyst
Just one day after the ascendant biotech CRISPR Therapeutics (NASDAQ: CRSP) reported its fourth-quarter earnings on Feb. 21, Chardan Capital analyst Geulah Livshits raised her price target for the
![Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeSt3V1E9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9dfca4603c1fc3af5c96a68f8938e1fa8ce6aed8/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/featured-transcript-logo-template-2023-01-12.jpg?locale=us)
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Sarepta Therapeutics (NASDAQ: SRPT)Q4 2023 Earnings CallFeb 28, 2024, 4:30 p.m. ET
Operator
Source Fool.com
![Is It Too Late to Buy Sarepta Therapeutics Stock?: https://g.foolcdn.com/editorial/images/766349/physician-giving-a-high-five-to-a-young-patient.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHRDYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--adf6485d3c52567cadc5cdc52c36b22f6b2837f1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/physician-giving-a-high-five-to-a-young-patient.jpg?locale=us)
Is It Too Late to Buy Sarepta Therapeutics Stock?
Sarepta Therapeutics (NASDAQ: SRPT), a midcap biotech company, was riding high 18 months ago. The company was awaiting a crucial regulatory approval from the U.S. Food and Drug Administration (FDA)
![Pfizer Stock Has 30% Upside, According to 1 Wall Street Analyst: https://g.foolcdn.com/editorial/images/766635/doctors-with-pharmaceutical-images.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFJBYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--99c11397a0099da657821e30f40b5de293235bf1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctors-with-pharmaceutical-images.jpg?locale=us)
Pfizer Stock Has 30% Upside, According to 1 Wall Street Analyst
With Pfizer (NYSE: PFE) stock hovering near a five-year low, one analyst has just started coverage of the pharmaceutical giant and is telling investors it's time to buy. In a report released last